| 5.3942 0.104 (1.97%) | 05-06 14:06 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.08 | 1-year : | 7.81 |
| Resists | First : | 6.06 | Second : | 6.69 |
| Pivot price | 5.52  |
|||
| Supports | First : | 5.05 | Second : | 4.2 |
| MAs | MA(5) : | 5.3 |
MA(20) : | 5.67 |
| MA(100) : | 8.58 |
MA(250) : | 8.4 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 15.4 |
D(3) : | 14.4 |
| RSI | RSI(14): 31.3 |
|||
| 52-week | High : | 12.25 | Low : | 5.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VALN ] has closed above bottom band by 33.2%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.37 - 5.4 | 5.4 - 5.43 |
| Low: | 5.17 - 5.21 | 5.21 - 5.25 |
| Close: | 5.23 - 5.29 | 5.29 - 5.34 |
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Wed, 06 May 2026
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026 - The Manila Times
Tue, 05 May 2026
Valneva Sets May 13 Date to Present First-Quarter 2026 Results - TipRanks
Tue, 05 May 2026
Valneva (VALN) schedules Q1 2026 results webcast for May 13 - Stock Titan
Fri, 24 Apr 2026
Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate - MSN
Sun, 19 Apr 2026
Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13 - Yahoo Finance
Thu, 16 Apr 2026
Guggenheim cuts Valneva stock price target to $11 on Lyme vaccine - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 87 (M) |
| Shares Float | 141 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 174 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | -66 % |
| Operating Margin | -58.1 % |
| Return on Assets (ttm) | -11.4 % |
| Return on Equity (ttm) | -80.2 % |
| Qtrly Rev. Growth | -9.9 % |
| Gross Profit (p.s.) | -0.21 |
| Sales Per Share | 2.01 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -3.36 |
| PEG Ratio | 0 |
| Price to Book value | 3.72 |
| Price to Sales | 2.65 |
| Price to Cash Flow | -8.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|